ArticleMicrobial cell factories2016
Deregulation of S-adenosylmethionine biosynthesis and regeneration improves methylation in the E. coli de novo vanillin biosynthesis pathway.
Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 114 citations in OpenAlex.
- Biosynthesis of vanillin glucoside inSynthetic and systems biotechnology · 2027Article
- Reconstituting a two-step pathway forMetabolic engineering communications · 2026Article
- Microbial production of xanthohumol driven by synthetic biology approaches.World journal of microbiology & biotechnology · 2026Review
- A versatile method for designing biosensors via regulatory domains of allosteric enzymes.Nature communications · 2026Article
- De novo biosynthesis of alpinetin enhanced by directed evolution of 5-O-methyltransferase.Microbial cell factories · 2026Article
- Article
- Developing a highly efficient whole-cell biotransformation of 3,4-dihydroxyacetophenone into Apocynin by engineered Escherichia coli expressing caffeic acid O-methyltransferase.World journal of microbiology & biotechnology · 2025Article
- De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli.Microbial biotechnology · 2025Article
- Engineering Caffeic Acid O-Methyltransferase for Efficient De Novo Ferulic Acid Synthesis.Engineering in life sciences · 2025Article
- Rewiring Escherichia coli to transform formate into methyl groups.Microbial cell factories · 2025Article
- Genetic Engineering Approaches for the Microbial Production of Vanillin.Biomolecules · 2024Review
- Bioproduction of methylated phenylpropenes and isoeugenol inMetabolic engineering communications · 2024Article
- Minimal aromatic aldehyde reduction (MARE) yeast platform for engineering vanillin production.Biotechnology for biofuels and bioproducts · 2024Article
- Engineering a Carboxyl Methyltransferase for the Formation of a Furan-Based Bioplastic Precursor.ChemSusChem · 2023Article
- Functional Diversification and Structural Origins of Plant Natural Product Methyltransferases.Molecules (Basel, Switzerland) · 2022Review
- Total enzymatic synthesis of cis-α-irone from a simple carbon source.Nature communications · 2022Article
- Production of (2Synthetic and systems biotechnology · 2022Article
- Article
- Methyltransferases: Functions and Applications.Chembiochem : a European journal of chemical biology · 2022Review
- Comparative Analysis of Catabolic and Anabolic Dehydroshikimate Dehydratases for 3,4-DHBA Production inMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVanillin is an industrially valuable molecule that can be produced from simple carbon sources in engineered microorganisms such as Saccharomyces cerevisiae and Escherichia coli. In E. coli, de novo production of vanillin was demonstrated previously as a proof of concept. In this study, a series of data-driven experiments were performed in order to better understand limitations associated with biosynthesis of vanillate, which is the immediate precursor to vanillin.
resultsTime-course experiments monitoring production of heterologous metabolites in the E. coli de novo vanillin pathway revealed a bottleneck in conversion of protocatechuate to vanillate. Perturbations in central metabolism intended to increase flux into the heterologous pathway increased average vanillate titers from 132 to 205 mg/L, but protocatechuate remained the dominant heterologous product on a molar basis. SDS-PAGE, in vitro activity measurements, and L-methionine supplementation experiments suggested that the decline in conversion rate was influenced more by limited availability of the co-substrate S-adenosyl-L-methionine (AdoMet or SAM) than by loss of activity of the heterologous O-methyltransferase. The combination of metJ deletion and overexpression of feedback-resistant variants of metA and cysE, which encode enzymes involved in SAM biosynthesis, increased average de novo vanillate titers by an additional 33% (from 205 to 272 mg/L). An orthogonal strategy intended to improve SAM regeneration through overexpression of native mtn and luxS genes resulted in a 25% increase in average de novo vanillate titers (from 205 to 256 mg/L). Vanillate production improved further upon supplementation with methionine (as high as 419 ± 58 mg/L), suggesting potential for additional enhancement by increasing SAM availability.
conclusionsResults from this study demonstrate context dependency of engineered pathways and highlight the limited methylation capacity of E. coli. Unlike in previous efforts to improve SAM or methionine biosynthesis, we pursued two orthogonal strategies that are each aimed at deregulating multiple reactions. Our results increase the working knowledge of SAM biosynthesis engineering and provide a framework for improving titers of metabolic products dependent upon methylation reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.